Pehea e hoʻohana ai iā Rotomox?

Pehea e hoʻohana ai i nā ʻōkuhi pūnaewele no nā papa a me nā lāʻau lapaʻau ʻē aʻe OnlineManuals.ru
ʻO kā mākou pahuhopu ke hāʻawi aku iā ʻoe i kahi wikiwiki i nā kiko o nā ʻōkuhi no ka lāʻau Rotomox. Me ke kōkua o ka nānā pūnaewele, hiki iā ʻoe ke nānā wikiwiki i nā kiko o nā ʻōkuhi no ka lāʻau Rotomox.

No kou ʻoluʻolu
Inā e haʻalele ʻoe i nā ʻōkuhi no ka hoʻohana ʻana no ka lāʻau Rotomox pono ma ka pūnaewele, ʻaʻole kūpono loa ia no ʻoe, aia nā hopena ʻelua:

• Nānā i ke ʻano helehelena piha - he mea maʻalahi ke nānā i nā ʻōkuhi no ka hoʻohana ʻana (me ka ʻole o ka hoʻouka ʻana i kāu kamepiula) hiki iā ʻoe ke hoʻohana i ke ʻano hiʻohiʻona piha. Ke ʻike nei i nā ʻōkuhi "no Rotomox i ka piha piha, e hoʻohana i ka pihi" Open ma Pdf-viewer ".
• Kākau i kahi kamepiula - Hiki iā ʻoe ke kiʻi i nā ʻōkuhi no ka mākaukau Rotomox ma kāu kamepiula a mālama iā ia i nā faila.

Nui ka poʻe e makemake e heluhelu i nā palapala ʻaʻole ma ka ʻaoʻao, akā ma ka paʻi. Ua hoʻolako ʻia ka mākaukau no ka paʻi ʻana i nā ʻōlelo aʻoaʻo no nā lāʻau a me nā papa i ko mākou pūnaewele, a hiki iā ʻoe ke hoʻohana iā ia ma ka kaomi ʻana ma ka “paʻi” icon ma ka Pdf-viewer. ʻAʻohe pono e paʻi i nā ʻōlelo holoʻokoʻa no ka hoʻomākaukau ʻana o Rotomox, hiki iā ʻoe ke koho wale nō i nā ʻaoʻao kūpono o ke aʻo no ka hoʻohana ʻana i kahi lāʻau lapaʻau a i ʻole kekahi papa.

Hiki ke hoʻoiho ʻia nā ʻōkuhi no ka hoʻohana ʻana i ka lāʻau ʻo Rotomox ma lalo nei:

ʻĀpana Pharmacological

Wahi a nā Papa kauka hōʻikeʻike kauka (2009), ua hōʻike ʻia ka moxifloxacin no ka mālama ʻana i nā maʻi i hoʻoiho ʻia e nā ʻōpala hikiʻole i nā microorganism i nā maʻi maʻi (ʻoi aku ka 18 mau makahiki keu).

Sinusitis huapalapala huehuemāe ʻia e Streptococcus pneumoniae, Haemophilus influenzae a i ʻole Moraxella catarrhalis.

ʻO ka hoʻōla o ka bronchitis maʻi i pili me kahi maʻi bacterial(Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, mikiikihiki Staphylococcus aureus a i ʻole Moraxella catarrhalis).

Loaʻa i ka maʻi pneumonia kaiaulumāe ʻia e ʻO ka maʻi pīkoi streptococcus (komo ma muli o ke kumu o nā microorganisms me nā kūmole pale a me ka pale ʻana), Haemophilus influenzae, Moraxella catarrhalis, mikiikihiki Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae a i ʻole ʻO ka pneumoniae a Chlamydia.

ʻO nā maʻi lēwa ʻole ka hoʻopili o ka ʻili a me nā mea pili iā ianā mākaʻi e ka mipoila Staphylococcus aureus a i ʻole ʻO nā pyogenes Streptococcus.

Hoʻopilikia i nā maʻi kuhihewakomo pū me nā polymicrobial maʻi e like me ka abscess form i hoʻokumu ʻia e Escherichia coli, Hoʻokomo nā huapili, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Hoʻolaha Clostridium, Hoʻokomo ʻia nā bakiole thetaiotaomicron a i ʻole Peptostreptococcus spp.

Nā maʻi ʻeha o ka ʻili o ka ʻili a me nā mea hoʻohuinā mākaʻi e ka mipoila Staphylococcus aureus, Escherichia coli, nā wāwae o Klebsiella a i ʻole Enterobacter cloacae.

* - ke kīwī me ka pale o ke aʻai kūʻokoʻa (Nui-lāʻau ke pale ʻO ka maʻi pīkoi streptococcus - MDRSP), me nā uaua o ka wā i kapa ʻia mua ʻia ʻo PRSP (kūʻa-Penicillin S. pneumoniae) a kūʻē i ke olakino i ʻelua a ʻoi aku paha i nā hopena ʻelua: penicillin (me MIC ≥2 μg / ml), nā cephalosporins mau lua (e.g. cefuroxime), macrolides, tetracyclines a me trimethoprim / sulfamethoxazole.

ʻŌpū a me ka lactation

Hiki paha ke hoʻohana ʻia inā hiki ke loaʻa ka hopena kūpono o ka ʻoi ma ka hiki ke mālama ʻia i ka wahine hāpai (ʻoiʻi a paʻa paʻa nā haʻawina no ka palekana o ka hoʻohana ʻana i nā wahine hāpai ʻaʻole i mālama ʻia.

Nā hopena teratogenic. ʻAʻohe o ka hopena teratogen i ka Moxifloxacin i ka wā i mālama ʻia ai i nā mea momona wahine i ka wā o ka organogenesis ma nā nui he nui ma mua o 500 mg / kg / lā, e pili ana i ka 0.24 MRDCH (e pili ana i nā waiwai o AUC), akā aia ka emi ʻana o ka nui o ke kino fetal a me kahi lohi i ka ulu ʻana o ka ʻūhā, e hōʻike ana. fetikixicity.

I ka hoʻokaʻawale ʻia ʻana o nā maʻi hānai me ka moxifloxacin ma kahi mahele o 80 mg / kg / lā (ma kahi o 2 mau manawa ʻoi aku ka nui o ka MPD, helu ʻia ma ke ʻano o ke kino (mg / m 2), ua nānā ʻia ka pehu me ka wahine a me ka hopena liʻiliʻi i ka pūpū, ke kaumaha a me ke ʻano o ka plasenta. Me nā kānana iv ma luna o 80 mg / kg / lā, ʻaʻohe i ʻike ʻia ka hopena teratogenic .. ʻĀpena IV i nā lālani i ka wā hānau ʻana i ka manawa o ka nui o ka organogenesis dosis o 20 mg / kg / lā (e pili ana i ka like me MPD i ka wā i lawe ʻia wahaheʻe) i alakaʻi i ka emi ʻana o ke kaumaha o ke kino fetal. a lohi i ka ossification o ka ʻūhā. ʻO nā hōʻailona o ka hona o nā wahine Aia ka loko o ka lethality, kuhihewa, ka hoʻokaʻawale ʻana i loko o ka inu meaʻai, ka hoʻokahe ʻana i ka inu ʻana i ka wai, a me ka hypoactivity i kēia mau wai, ʻAʻohe mea hōʻike wahaheʻe o teratogenicity ma nā māka Cynomolgus ma kahi o nā 100 mg / kg / lā (2.5 MRDI). hoʻonui ʻia ma ka pā o 100 mg / kg / lā. Ma nā lālau, ua ʻike ʻia me ka nui o ka waha o ka 500 mg / kg / lā, ua ʻike ʻia nā hopena like ʻole: ke hoʻolōʻihi iki nei ka lōʻihi o ka wā hapai, lilo ka prenatal, hōʻemi i ka paona i ka pēpē hou ke ui, ua hoʻemi neonatal ola. Ka hopena i ka hopena o ka moxifloxacin ma luna o ka mea maʻi i ka wā i hōʻike ʻia ai kahi nui o 500 mg / kg / lā i nā lālani i ka wā hāpai.

Hana Hana FDA C.

Hoʻokā ʻia ka Moxifloxacin i loko o ka umauma waiū o nā mauʻu. No ka hiki ke lilo ʻoxifloxacin i ka umauma waiū o nā wahine hānai a hiki i nā hopena ʻino loa i nā pēpē hānai ʻia, ʻoi aku nā wahine kahu hānai i ka hānai umauma a i ʻole ka hoʻohana ʻana i ka moxifloxacin (i hāʻawi ʻia i ka mea nui o ka lāʻau i ka makuahine).

Nā hopena hopena

I ka wā o nā hoʻokolohua lapaʻau e pili ana i nā mea maʻi ma mua o 9,200 i loaʻa i ka moxifloxacin ma ke alo a me ka iv (ma luna o 8600 nā mea maʻi i loaʻa iā ia ma kahi o 400 mg) ka hapanui, ʻo ka hapa nui o nā hopena ʻaoʻao i hōʻino ʻia a maʻalahi hoʻi, ʻaʻole i koi i ka hoʻokuʻu ʻana o ka hoʻomaʻamaʻa. Ua hoʻokuʻu ʻia ka Therapy ma muli o ka hiki ʻana o nā hopena ʻaoʻao e pili ana i ka lāʻau lapaʻau ma ka 2.9% o nā mea maʻi i ka wā e lawe ai i ka maʻi a me ka 6.3% o nā maʻi i loaʻa iā ia me ke ʻano (iv a orally).

ʻO nā hopena hope loa i helu ʻia ma ka liʻiliʻi loa e pili ana i ka lāʻau lapaʻau a nānā ʻia i ≥2% o nā mea maʻi: nausea (6%), nā maʻi maʻi (5%), hupa (2%).

Ua hōʻike ʻia nā hopena o ka maʻi i hōʻike ʻia e like me ka liʻiliʻi loa e pili ana i ka lāʻau lapaʻau a nānā ʻia i QT, leukopenia, hoʻoneʻe prothrombin (hoʻonui i ka manawa prothrombin / hoʻonui INR), eosinophilia, thrombocythemia, ECG, hypertension, hypotension, peripheral edema, hoʻonui prothrombin (ka hōʻemi i ka manawa prothrombin / hōʻemi i loko o INR), thrombocytopenia, tachycardia supraventricular, hoʻemi i ka thromboplastin, tachycardia ventricular.

Mai ka hāliʻi ʻana o ka huina: ≥0.1% komo ʻeha ma loko o ka ʻāʻī, ke kua, nā wāwae, nā maʻi pelvic, ʻōpū o ka hoʻi, ka māla ʻana o ke alo, hyperglycemia, hyperlipidemia, hypertension, hypesthesia, photosensitivity / phototoxicity reaksi, syncope, tenopathy.

I noiʻi noiʻi-post Ua hōʻike ʻia nā hopena pili hope loa: nā hopena anaphylactic, angioedema (me ka laryngeal edema), hōʻeha ate (me nā hihia hōʻeha), hepatitis (ʻoi aku ka cholestatic), nā photosensitivity / phototoxicity kūmole, hopena psychotic, Stevens-Johnson syndrome, tendon rupture, toxic epidermal necrolysis a me ka tachyarrhythmia ventricular (me nā hihia nui loa i hopu ʻia i ka cardiac a hune de pointes ka mea maʻamau i ka poʻe maʻi me nā hōʻailona koʻikoʻi proarrhythmic koʻikoʻi).

ʻO nā mea mālama palekana

E kū'ē i ka kiʻi o moxifloxacin, no laila, hiki ke hoʻonui ʻia ka waena o ka QT, no laila, pono e hoʻohana ʻia me ka akahele i ka poʻe maʻi e loaʻa ana i nā lāʻau lapaʻau hou i ka manawa like pū me ka hoʻolalelale ʻana i ka manawa QT (cisapride, erythromycin, antipsychotics, anticyepresi tricyclic), no ka mea ʻaʻole hiki ke hoʻoholo ʻia ka hopena hoʻohui.

Me ka makaʻala, ua kuhikuhi ʻia lākou i ke ʻano o nā lāʻau antiarrhythmic o ka papa IA (quinidine, procainamide) a i ka papa III (amiodarone, sotalol).

Ma muli o ka liʻiliʻi o ka ʻikepili ma o ka hoʻohana ʻana i ka moxifloxacin i nā mea maʻi me ka bradycardia koʻikoʻi i nā maʻi a me nā hōʻailona o ka ischemia myocardial akui, pono e hoʻohana ʻia me ka makaʻala i kēia mau maʻi. Hiki ke hoʻonui ʻia i ka lōʻihi o ka neʻe o ka manawa QT me ka hoʻonui ʻana i ka manaʻo a me ka hoʻonui ʻana o ka infusion me ka hoʻomalu iv, no laila, ʻaʻole i hoʻonui ʻia nā ʻano i ʻōlelo ʻia a me nā manawa o ka hoʻokele. Hiki i ke hoʻonui ʻana i ke kikowaena QT ke alakaʻi i ka nui o ka pilikia o nā arrhythmias ventricular, ʻo ia hoʻi hune de pointes. ʻAʻole nā ​​hihia o ka morbidity a i ʻole ka make me ka hoʻolalelale ʻana o ka manawa QT ma nā hoʻokolohua olakino e hoʻohana ana i ka moxifloxacin ma mua o 9,200 mau maʻi (me ka poʻe 223 nā mea maʻi me ka hypokalemia i ka hoʻomaka ʻana o ka mālama ʻana), a ʻaʻohe mea i hoʻonui i ka make ma ka make me 18 tausani nā mea maʻi e lawe ana i ka moxifloxacin i loko, i ka manawa o ka noiʻi post-marketing me ka ʻole ka mana o ECG.

Hoʻohui ʻia ka hoʻohana ʻana o ka quinolones me ka hopena o ka ulu ʻana o nā mea hoʻoweliweli hoʻokūkū, a me nā pilikia ʻē aʻe o ka pūnaehana hoʻonāukiuki (dizziness, confing, tremor, hallucinations, ʻehaʻeha, a me nā mea maʻamau, nā manaʻo suicidal a i ʻole hana). Hiki ke nānāʻia kēia mau mea ma hope o ka hopena mua o ka lāʻau. I ka hanana ʻana o nā ʻano pane, pono e hoʻokuʻu ʻia ka moxifloxacin. E like me nā quinolones ʻē aʻe, pono e hoʻohana ʻia ka moxifloxacin me ka makaʻala i ka manawa a i ʻole ke kānalua o ka maʻi hanana ʻōnaehana waena (komo pū kekahi cerebral arteriosclerosis, epilepsy) a i mua paha o nā mea ʻē aʻe e wānana ana i ka loaʻa ʻana o nā mea hoʻokuʻi a i ʻole ka hōʻemi ʻana i ka paepae hoʻoiho.

ʻO nā hihia o ka hoʻomohala ʻana i nā hopena anaphylactic koʻikoʻi i ka wā e lawe ai i ka lāʻau lapaʻau i nā poʻe maʻi e lawe ana i ka quinolones, me ka moxifloxacin, ua hōʻike ʻia. I kekahi mau hihia, ua ukali ʻia kēia mau hopena me ka hina ʻana o ka puʻuwai, nalowale o ka ʻike, nāwaliwali, huehue o ka ʻāʻī a i ʻole ke alo, dyspnea, urticaria, a me ka ʻeha. I ka hihia o nā anaphylactic hopena, koi ʻia ka hoʻokele o ka epinephrine. Inā loaʻa kahi ʻōmole a i ʻole nā ​​hōʻailona ʻē aʻe o ka hopena o ka hypersensitivity, pono e hoʻihoʻi ʻia ka moxifloxacin a i ʻole e hana ʻia nā hana resuscitation kūpono (inā pono).

He mea nui ia e noʻonoʻo i ka hiki ke hoʻomohala ʻana i ka colitis pseudomembranous, inā inā hele nā ​​maʻi maʻi i nā mea e loaʻa ana i nā ʻāpana antibacterial. Ke alakaʻi nei me ka maʻi antibacterial e hoʻohuli i ka maʻamau o ka flora maʻamau o ka ʻōpū nui a hiki ke alakaʻi i ka ulu ʻana o ka clostridia. Ke hoʻomaka nei kahi hōʻike maʻi o ka colitis pseudomembranous, pono e hoʻomaka i ka lāʻau kūpono.

I ka wā o ka maʻi me ka fluoroquinolones, e komo moxifloxacin, hiki i ka hoʻomohala ʻana o ka tendonitis a me ka tendture tendon (Achilles a me kekahi mea). Ua hōʻike ka nānā ʻana o ka kūʻai aku ʻana ma hope o ka kūʻai ʻana i ka nui o ka maʻi i nā poʻe maʻi e loaʻa ana i nā corticosteroids, ʻoi aku ka nui o nā makahiki 60. No laila, i ka wā o ka hōʻeha, ka ʻeha a i ʻole nā ​​luhi o ka tendon e hele, e hoʻokaʻawale ke keʻena o moxifloxacin. Pono e noʻonoʻo i ka wā hiki i ka wā hiki i ka wā hiki ke hōʻeha a wā ʻia ma hope o ka therapy quinolone (me ka moxifloxacin).

Nā ʻōlelo kikoʻī

Ma mua o ka hoʻōla ʻana, pono e hana i nā hoʻokolohua kūpono e ʻike ai i nā microorganisms i loaʻa ai ka maʻi a me ka nānā aku i ka naʻau o ka moxifloxacin. Hiki ke hoʻomaka ʻia ke ʻano ʻo Moxifloxacin ma mua o ka loaʻa ʻana o nā hopena o kēia mau hoʻokolokolo. Ke ʻike ʻia nā hopena hōʻike, pono e hoʻomau ʻia ka lāʻau kūpono.